Rimegepant
- Generic Name
- Rimegepant
- Brand Names
- Nurtec, Vydura
- Drug Type
- Small Molecule
- Chemical Formula
- C28H28F2N6O3
- CAS Number
- 1289023-67-1
- Unique Ingredient Identifier
- 997WVV895X
- Background
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists of CGRP and its re...
- Indication
Rimegepant is indicated for the acute treatment of migraine with or without aura in adults. Rimegepant is also indicated for the prevention of episodic migraine in adults.
- Associated Conditions
- Episodic Migraine, Migraine With Aura, Migraine Without Aura
- Associated Therapies
- -
The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 300
- Registration Number
- NCT06728345
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 723
- Registration Number
- NCT06641466
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT06616194
- Locations
- 🇯🇵
Tominaga Clinic, Osaka-Shi, Osaka, Japan
🇺🇸Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States
🇺🇸Granger Medical Holladay - Holladay Clinic, Salt Lake City, Utah, United States
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Antonios Likourezos
- Target Recruit Count
- 80
- Registration Number
- NCT06473597
- Locations
- 🇺🇸
Maimonides Medical Center, Brooklyn, New York, United States
ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 3000
- Registration Number
- NCT06439628
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital Zhejiang University School of Medicine, Hang Zhou, Zhenjiang, China
A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area
- Conditions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-04-11
- Target Recruit Count
- 120
- Registration Number
- NCT06221267
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Migraine Medication Effects on Urinary Symptoms
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT06212661
- Locations
- 🇺🇸
Cleveland Clinic, Main Campus, Cleveland, Ohio, United States
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 784
- Registration Number
- NCT05810038
- Locations
- 🇨🇳
Lanzhou university second hospital, Lanzhou, Gansu, China
🇨🇳The Second People's hospital of Hefei, Hefei, Anhui, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT05518123
- Locations
- 🇪🇸
Hospital Universitario Ruber Juan Bravo, Salamanca, Madrid, Spain
🇺🇸Clinical Research Institute, Los Angeles, California, United States
🇺🇸California Neuroscience Research, LLC, Sherman Oaks, California, United States
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT05509400
- Locations
- 🇪🇸
Hospital Universitario Ruber Juan Bravo, Salamanca, Madrid, Spain
🇺🇸Clinical Research Institute, Los Angeles, California, United States
🇺🇸Ki Health Partners LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.